AstraZeneca has struck a deal to combine its anti-PD-L1 drug with NewLink Genetics’ IDO pathway inhibitor. The collaborators will jointly fund a phase 2 trial of the combination in pancreatic cancer patients. http://www.fiercebiotech.com/biotech/astrazeneca-newlink-pen-pd-l1-and-ido-combination-pact
Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
The post Novartis’ CAR-T drug needs new payment model, says Express Scripts appeared first on Pharmaphorum. https://pharmaphorum.com/news/novartis-car-t-expensive-us-health-system-express-scripts/
As Health Care Industry is projected to grow by 17% (compounded annual growth rate) by 2020; startups are attempting to overcome problems such as poor health infrastructure, low levels of insurance, and rural vs urban disparity that are plaguing health services in India. https://www.forbes.com/sites/krnkashyap/2017/09/25/how-startups-are-trying-to-overcome-indias-healthcare-challenges/
The United States is the global leader in biomedical innovation, discovering more new cures than … http://www.biotech-now.org/health/2017/09/new-infographic-a-response-to-a-better-deal-on-drug-pricing
The positive results in the clinical trial help validate Alnylam’s $7 billion market valuation and pave the way for more drugs based on RNAi technology. https://www.statnews.com/2017/09/20/alnylam-drug-success/
Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined. http://www.biopharmadive.com/news/bristol-roche-tap-halozyme-for-tech-platform/504958/
At the European Academy of Dermatology and Venereology Congress in Geneva, Switzerland, Novartis unveiled new Phase 3 data for Cosentyx (secukinumab) evidencing its long term skin clearance benefits and safety profile in the treatment of psoriasis.
read more http://www.pharmafile.com/news/515108/novartis-cosentyx-proves-long-term-efficacy-psoriasis-skin-clearance
NewsCOPD, a progressive lung disease characterized by airway obstruction and chronic lung inflammation, affects 30 million Americans.Contributed Author: University of Pittsburgh School of Health SciencesTopics: Drug Discovery https://www.dddmag.com/news/2017/09/precision-therapy-proves-effective-treatment-resistant-subgroup-copd-patients
Dexcom G5 Mobile data will be displayed on Fitbit’s Ionic smartwatch.
The post Fitbit and Dexcom to bring diabetes data to Ionic smartwatch appeared first on Pharmaphorum. https://pharmaphorum.com/news/fitbit-dexcom-ionic-smartwatch/
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn. http://www.biopharma-reporter.com/Upstream-Processing/Gilead-aims-to-expand-CAR-T-manufacturing-post-Kite-acquisition